Icahn School of Medicine at Mount Sinai shared a post on LinkedIn:
“Immunotherapy is transforming the outlook for patients with multiple myeloma. At Mount Sinai, researchers are advancing innovative treatments – including CAR T cell therapy and bispecific antibodies – that are delivering unprecedented response rates in patients with relapsed or refractory disease.
Findings from the CARTITUDE-1 trial show that one-third of patients treated with CAR T therapy remained progression-free for five years or more, signaling the possibility that long considered incurable multiple myeloma may, for some patients, now be within reach of a cure.”
Other articles from Icahn School of Medicine at Mount Sinai.